EPIX - Essa Pharma jumps 91% on Phase 1/2 data for prostate cancer therapy

• Canadian biotech ESSA Pharma Inc. ( NASDAQ: EPIX ) added 91% in the morning hours Wednesday after announcing Phase 1/2 data for a prostate cancer therapy combining its lead asset EPI-7386 with enzalutamide developed by Pfizer ( PFE ) and Astellas Pharma ( OTCPK:ALPMF ) ( OTCPK:ALPMY ).
• Citing an upcoming presentation on the first two cohorts of the multicenter, open-label trial, EPIX said that the combination regimen indicated a favorable safety profile with no dose-limiting toxicities in seven patients with metastatic castration-resistant prostate cancer ("mCRPC").
• While four of six patients achieved a PSA90 after 12 weeks of dosing, the company said five patients had demonstrated a PSA90 so far, implying a sustainable prostate-specific antigen ("PSA") reduction. One patient was not evaluable due to discontinuation.
• In preparation for a Phase 2 trial, EPIX is enrolling patients for a third dose escalation cohort to find the optimum dose.

For further details see: